新辅助化疗/免疫检查点抑制三阴性乳腺癌中的急性表现:来自现实世界的数据的经验和影响
Tim Cooksley1, Safwaan Adam2, Bence Nagy1
1The Christie NHS Foundation Trust, Manchester, United Kingdom.
Breast (Edinburgh, Scotland)
|July 27, 2025
概括
在接受新辅助化疗和免疫检查点抑制剂 (ICI) 的早期三阴性乳腺癌患者中,急性表现往往与ICI无关. 这一发现表明,需要更新临床指南来管理这种特定患者群体中毒性的情况.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 免疫检查点抑制剂 (ICI) 治疗与化疗相结合,在早期三阴性乳腺癌的新辅助治疗中显示出益处.
- 在接受联合化疗/ICI治疗的患者中,急性呈现会带来临床挑战和资源影响.
研究的目的:
- 评估早期三阴性乳腺癌患者接受新辅助化疗和ICI治疗的急性表现的原因.
- 确定可归因于ICI相关毒性的急性表现的比例.
主要方法:
- 在英格兰的一家专业瘤医院进行的前性分析.
- 主要结局:确定ICI相关的毒性是急性表现的原因.
- 二次结局:住院病床日,发生3级以上的腹或因ICI毒性而引起的转氨酶升高的发生率.
主要成果:
- 在285名患者中,168人有210例紧急情况.
- 25.2%的急性表现被诊断为ICI相关的毒性.
- 显著的住院资源利用率为576个卧床日;只有少数严重的腹或转氨酶升高是ICI介导的.
结论:
- 在三阴性乳腺癌的新辅助疗法中,只有四分之一的急性表现是由免疫检查点抑制剂毒性驱动的.
- 这种联合治疗队列中的毒性可能与单独使用化疗或ICI治疗的人不同.
- 新的临床实践指导可能需要在接受联合新辅助化疗和ICI治疗的患者中管理急性表现.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
5.1K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.6K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
